Export

EN
FR
Cytarabine
Essential medicine status
Section:
8. Immunomodulators and antineoplastics 8.2. Antineoplastics and supportive medicines 8.2.1. Cytotoxic medicines
ATC codes: L01BC01
EMLc
Indication
Acute myeloid leukaemia with recurrent genetic abnormalities ICD11 code: 2B30.0
INN
Cytarabine
Medicine type
Chemical agent
List type
Complementary (EML)
(EMLc)
Formulations
Parenteral > General injections > unspecified: 100 mg in vial powder for injection ; 100 mg per mL in vial
EML status history
First added in 1979 (TRS 641)
Changed in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Changed in 2023 (TRS 1049)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Tags
Wikipedia
Cytarabine
DrugBank
Cytarabine
Summary of evidence and Expert Committee recommendations
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of cytarabine (100 mg/mL in vial) to the EML and EMLc.